

INTERLEUKIN GENETICS INC  
Form 8-K  
June 12, 2006

## UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

## FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) **June 6, 2006**

## Interleukin Genetics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

## Delaware

(State or Other Jurisdiction of Incorporation)

**001-32715**

(Commission File Number)

**94-3123681**

(IRS Employer Identification No.)

**135 Beaver Street Waltham, MA**

(Address of Principal Executive Offices)

**02452**

(Zip Code)

**(781) 398-0700**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

(b) On June 6, 2006, William J. Viveen, Jr. resigned as a director of the Registrant and Dianne E. Bennett was elected to replace Mr. Viveen in that capacity. Ms. Bennett was elected pursuant to the provisions of the Registrant's Restated Certificate of Incorporation by the directors remaining in office that were elected by the holder of the Registrant's Series A Convertible Preferred Stock. The Registrant expects Ms. Bennett to be elected to the following committees of the Board of Directors: Audit, Compensation and Nominating.

2

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Interleukin Genetics, Inc.**  
(Registrant)

Date: June 12, 2006

**/s/ KENNETH S. KORNMAN**  
**Kenneth S. Kornman**  
**Chief Executive Officer, President and**  
**Chief Scientific Officer**  
(Signature)